1-<<2-(diethylamino)ethyl>amino>-7-(toluenesulfonyloxy)-4-(hydroxymethyl)-9H-xanthen-9-one | 86456-21-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 1-<<2-(diethylamino)ethyl>amino>-7-(toluenesulfonyloxy)-4-(hydroxymethyl)-9H-xanthen-9-one
• 英文别名: 1-{[2-(diethylamino)ethyl]amino}-7-(toluenesulfonyloxy)-4-(hydroxymethyl)-9H-xanthen-9-one；9H-Xanthen-9-one, 1-((2-(diethylamino)ethyl)amino)-4-(hydroxymethyl)-7-(((4-methylphenyl)sulfonyl)oxy)-；[8-[2-(diethylamino)ethylamino]-5-(hydroxymethyl)-9-oxoxanthen-2-yl] 4-methylbenzenesulfonate
• CAS: 86456-21-5
• 化学式: C₂₇H₃₀N₂O₆S
• 分子量: 510.611
• InChiKey: QFLKRNMJXQIZEE-UHFFFAOYSA-N

物化性质

• 沸点：
  717.6±60.0 °C(Predicted)
• 密度：
  1.320±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  36
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  114
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  1-<<2-(diethylamino)ethyl>amino>-7-(toluenesulfonyloxy)-4-(hydroxymethyl)-9H-xanthen-9-one 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 反应 0.5h， 以90%的产率得到NSC355357
  参考文献：
  名称：

  Analogs of hycanthone and lucanthone as antitumor agents

  摘要：

  Hycanthone analogues (5 and 6) containing 7-substituted hydroxyl groups were prepared and evaluated as antitumor agents. These compounds were significantly more active than the corresponding unsubstituted derivatives. The 7-hydroxylated 4-(hydroxymethyl)-9H-xanthen-9-ones, 11 and 12, were also active antitumor agents. However, the 7-hydroxy-9H-xanthen-9-one counterparts of the 7-hydroxylucanthones were totally devoid of antitumor activity. Results obtained thus far are consistent with the hypothesis that 4-hydroxymethyl substituents in the 9H-xanthen-9-one and 9H-thioxanthen-9-one series are required for antitumor activity.

  DOI：

  10.1021/jm00363a007
• 作为产物：
  描述：

  1-<<2-(diethylamino)ethyl>amino>-7-hydroxy-9H-xanthen-9-one 在 吡啶 、 溶剂黄146 作用下， 反应 73.5h， 生成 1-<<2-(diethylamino)ethyl>amino>-7-(toluenesulfonyloxy)-4-(hydroxymethyl)-9H-xanthen-9-one
  参考文献：
  名称：

  Analogs of hycanthone and lucanthone as antitumor agents

  摘要：

  Hycanthone analogues (5 and 6) containing 7-substituted hydroxyl groups were prepared and evaluated as antitumor agents. These compounds were significantly more active than the corresponding unsubstituted derivatives. The 7-hydroxylated 4-(hydroxymethyl)-9H-xanthen-9-ones, 11 and 12, were also active antitumor agents. However, the 7-hydroxy-9H-xanthen-9-one counterparts of the 7-hydroxylucanthones were totally devoid of antitumor activity. Results obtained thus far are consistent with the hypothesis that 4-hydroxymethyl substituents in the 9H-xanthen-9-one and 9H-thioxanthen-9-one series are required for antitumor activity.

  DOI：

  10.1021/jm00363a007

文献信息

• ARCHER, S.
  作者：ARCHER, S.

  DOI：——

  日期：——
• Detection of biological DNA
  申请人：Roche Diagnostics GmbH

  公开号：EP1762629B1

  公开（公告）日：2009-11-11
• ACE2 ACTIVATOR COMPOUNDS AND METHODS OF USE THEREOF
  申请人：University of Florida Research Foundation, Inc.

  公开号：EP2101575A2

  公开（公告）日：2009-09-23
• Detection of biological DNA
  申请人：Birkner Christian

  公开号：US20070111234A1

  公开（公告）日：2007-05-17

  The present invention provides a method, a kit and a system for the analysis of samples with respect to the presence of biological DNA based on real-time polymerase chain reaction (PCR) in combination with an analyzing step. The method comprises the steps of performing a universal real-time PCR to amplify biological DNA in the sample, and analyzing the amplified biological DNA using a mass spectrometer (MS).
• [EN] ACE2 ACTIVATOR COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS ACTIVATEURS DE L'ACE2 ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：UNIV FLORIDA

  公开号：WO2008066770A2

  公开（公告）日：2008-06-05

  [EN] The invention relates to methods of treating cardiovascular and cardiopulmonary diseases and associated conditions, including hypertension. The invention further relates to pharmaceutical compositions for treating cardiovascular and cardiopulmonary diseases, especially hypertension, and lung injury.
  [FR] L'invention concerne un procédé de traitement de maladies cardiovasculaires et cardio-pulmonaires et des affections associées comprenant l'hypertension. L'invention concerne en outre des compositions pharmaceutiques destinées à traiter des maladies cardiovasculaires et cardio-pulmonaires, spécialement l'hypertension, et une défaillance pulmonaire.